The Novavax COVID-19 Vaccine, Adjuvanted is a protein subunit vaccine originally approved for EUA by the FDA on July 13, 2022. The EUA was amended on October 3, 2023, to include the 2023–2024 formula, a monovalent vaccine that has been updated to include the S protein from the Omicron variant XBB.1.5. The original monovalent vaccine is no longer in use. The 2023–2024 formula is authorized for individuals 12 years and older.
Novavax uses an adjuvant called Matrix-M, which comes from saponins, naturally occurring compounds in the bark of the soapbark tree (Quillaja saponaria).
